CardioDx
- Company typePrivate
- Founded2004
- HeadquartersRedwood City, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
CardioDx firmographics
Firmographics- Name
- CardioDx
- Website
- https://cardiodx.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
CardioDx industry classification
Industry- Product category
- Cardiovascular Genomic Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industry
- Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)
Keywords
Where CardioDx is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Markets served
CardioDx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
CardioDx product offering
Product offeringCore offering
CardioDx is a cardiovascular genomic diagnostics company that develops and provides AI-enabled in vitro diagnostics (IVD) for clinical use. Its offerings apply proprietary artificial intelligence algorithms to clinical chemistry, molecular diagnostics, pathology, genomics, and point-of-care testing, delivering diagnostic information that clinicians use to enhance patient care, particularly in cardiovascular and precision-medicine applications.
Product overview
CardioDx is a diagnostic company that develops AI-enabled in vitro diagnostics (IVD). The company competes on algorithm performance, data quality, and regulatory approval status in the AI-enabled IVD market. However, the provided sources do not contain specific product names, detailed descriptions, or portfolio information.
Differentiator
Problem solved
Functional benefit
Companies that use CardioDx
Customer profileSegments2 records
Ideal customer profiles2 records
CardioDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
CardioDx partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
CardioDx competitors and assessment
Company assessmentDirect peers
- Myriad Genetics: Myriad Genetics is a molecular diagnostics company focused on genomic tests that inform treatment decisions, particularly in oncology and other specialty areas. It is directly comparable to CardioDx as a specialty IVD franchise built on proprietary genomic assays sold into clinical practice, with a similar regulatory-and-reimbursement-driven business model.
- Veracyte: Veracyte is a genomic diagnostics company that develops molecular tests leveraging RNA sequencing and AI to resolve diagnostic ambiguity in specialty areas. It is comparable to CardioDx in being a specialty IVD company combining genomic/AI analysis with regulatory-cleared LDT or IVD tests sold through clinical channels.
- Guardant Health: Guardant Health is a leading precision oncology company specializing in blood-based (liquid biopsy) genomic testing. It is comparable to CardioDx as a blood-sample-driven, AI-enabled specialty diagnostics franchise with regulatory clearances and a focus on non-invasive decision-support testing in a defined clinical specialty.
- Genomic Health (acquired by Exact Sciences): Genomic Health pioneered genomic diagnostics in oncology with the Oncotype DX test, a category-creating IVD franchise. It is directly comparable to CardioDx as a specialty genomic test developer whose commercial success hinged on clinical validation, regulatory milestones, and reimbursement — the same value drivers for a cardiovascular genomic IVD.
- Natera: Natera is a cell-free DNA and genetic testing company whose core franchise spans reproductive health, oncology, and organ health. It is comparable to CardioDx as a specialty molecular diagnostics franchise with multiple cleared indications and a reimbursement- and clinical-evidence-driven commercial model.
Broad incumbents
- Exact Sciences: Exact Sciences is a major molecular diagnostics company, best known for Cologuard, with an expanding menu of genomic tests across multiple specialties following its acquisition of Genomic Health. It is comparable to CardioDx as a large-scale specialty IVD operator pursuing platform expansion via regulatory-cleared molecular tests and AI/ML-enabled analysis.
- Foundation Medicine (Roche): Foundation Medicine is a molecular information company providing genomic profiling services to oncologists, now owned by Roche. It is comparable to CardioDx as a high-complexity specialty genomic diagnostics franchise reliant on AI-assisted interpretation, clinical validation, and payer reimbursement — ultimately serving as a model for acquisition by large strategics.
- Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies in the U.S., with an advanced diagnostics franchise including cardiovascular and genomic specialty tests. It is comparable to CardioDx as a scaled clinical lab buyer and partner-of-choice for specialty IVD developers seeking national distribution and payer coverage.
- Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network with significant specialty/esoteric diagnostics franchise and extensive payer reach. It is comparable to CardioDx both as a potential commercialization partner and as a competitive incumbent that operates in the cardiovascular diagnostics space with broad distribution and established reimbursement.
Emerging players
- NeoGenomics: NeoGenomics is a clinical diagnostics laboratory specializing in oncology genetic testing, with growing specialty franchise reach. It is comparable to CardioDx as a specialty clinical diagnostics franchise combining proprietary assays, AI/algorithm-driven interpretation, and a hospital/clinic go-to-market motion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
CardioDx social profiles
Digital presenceCardioDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardioDx leadership team
Management profileNumber of profiles
Profiles1 record
CardioDx funding detail
Funding detailFunding overview
Funding rounds12 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardioDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardioDx
What does CardioDx do?
CardioDx is a cardiovascular genomic diagnostics company that develops and provides AI-enabled in vitro diagnostics (IVD) for clinical use. Its offerings apply proprietary artificial intelligence algorithms to clinical chemistry, molecular diagnostics, pathology, genomics, and point-of-care testing, delivering diagnostic information that clinicians use to enhance patient care, particularly in cardiovascular and precision-medicine applications.
When was CardioDx founded?
CardioDx was founded in 2004. It employs 51 to 100 people.
Where is CardioDx based?
CardioDx is headquartered in Redwood City, United States, in the North America region.
Who are CardioDx's main competitors?
Direct peers on record are Myriad Genetics, Veracyte, Guardant Health, Genomic Health (acquired by Exact Sciences) and Natera. Broad incumbents are Exact Sciences, Foundation Medicine (Roche), Quest Diagnostics and Laboratory Corporation of America (Labcorp). NeoGenomics is listed as an emerging player.
Does CardioDx have an API?
No public API is recorded for CardioDx.
What industry is CardioDx in?
CardioDx's product category is Cardiovascular Genomic Diagnostics. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG). Its NAICS code is 62151 and its SIC code is 2835.